ertapenem has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
| Alp Cavus, S; Avkan-Oguz, V; Eren Kutsoylu, O; Ergon, MC; Irmak, C; Kuruüzüm, Z; Nazli Zeka, A | 1 |
1 trial(s) available for ertapenem and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales.
Topics: Agar; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; COVID-19; Cyclooctanes; Ertapenem; Escherichia coli; Humans; Microbial Sensitivity Tests; Piperidines; SARS-CoV-2 | 2022 |
1 other study(ies) available for ertapenem and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Daily inpatient ertapenem therapy can be an alternative to hospitalization for the treatment of complicated urinary tract infections during the COVID-19 pandemic.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; COVID-19; Ertapenem; Escherichia coli Infections; Hospitalization; Humans; Inpatients; Pandemics; Retrospective Studies; SARS-CoV-2; Urinary Tract Infections | 2021 |